Inflammatory mediators and cartilage degradation pathways

Inflammatory mediators and cartilage degradation pathways represent the integrated molecular processes that drive the destruction of joint tissues in arthritic conditions. This system involves the production of pro-inflammatory cytokines, most notably Interleukin-1 beta (IL-1β) and Tumor Necrosis Factor-alpha (TNF-α), which stimulate chondrocytes to produce degradative enzymes (Goldring & Goldring, 2011). These enzymes, including matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), break down the collagen and proteoglycan components of the cartilage extracellular matrix (Burrage et al., 2006). Intracellular signaling through the NF-κB and MAPK pathways further amplifies this catabolic state, leading to joint space narrowing and functional disability (Kapoor et al., 2011). Therapeutic strategies often focus on inhibiting these specific mediators or their receptors to halt the catabolic process and preserve joint function. While not a single molecular target, these pathways are a primary focus for developing disease-modifying osteoarthritis drugs (DMOADs).

Other names

Cartilage catabolic pathwaysOsteoarthritis inflammatory signalingChondrocyte degradation cascade

Inhibition of pro-inflammatory cytokines (TNF-alpha, IL-1) and downstream catabolic enzymes (MMPs) to prevent extracellular matrix breakdown.